{
    "clinical_study": {
        "@rank": "149607", 
        "acronym": "PORTICO-1", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "description": "Patients implanted with a Portico valve bearing the CE mark (implanted after St Jude Medical declared the device \"compliant\" with all applicable essential requirements within the European union and marketed the device bearing the CE mark.)"
            }, 
            {
                "arm_group_label": "Cohort B", 
                "description": "Patients implanted with a Portico valve as part of an Investigational Device study."
            }
        ], 
        "brief_summary": {
            "textblock": "Further assess the performance and safety profile of the commercially available Portico\n      Valve implanted, using the Delivery System and the Loading System, in patients with severe\n      symptomatic aortic stenosis."
        }, 
        "brief_title": "5 Year Observation of Patients With PORTICO Valves", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Valve Stenosis", 
        "condition_browse": {
            "mesh_term": [
                "Aortic Valve Stenosis", 
                "Constriction, Pathologic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has signed the Patient Informed Consent prior to participating in the\n             clinical investigation.\n\n          -  Patient has been referred for a Portico Valve implant as per Heart Team decision.\n\n          -  Patient has senile degenerative aortic stenosis with an initial valve area of less\n             than (<) 1.0 cm2 (or aortic valve area index less than or equal to (\u2264) 0.6 cm2/m2)\n             AND a mean transvalvular gradient greater than (>) 40mmHg or jet velocity greater\n             than (>) 4.0 m/s derived by resting echocardiogram [or dobutamine stress\n             echocardiogram if subject has a left ventricular ejection fraction (LVEF) < 50%].\n             (Baseline measurement taken by echo within 45 days of index procedure).\n\n          -  Patient has a life expectancy more than (>) 12 months.\n\n        Exclusion Criteria:\n\n          -  Any case in which the Portico Valve would not be indicated for the patient as per\n             current instructions for use (i.e any \"off-label\" use).\n\n          -  Patient has a bicuspid aortic valve.\n\n          -  Patient has a prosthetic valve or ring in the aortic position.\n\n          -  Patient needs a concomitant structural heart procedure.\n\n          -  Patient needs the usage of an embolic protection device.\n\n          -  Patient is unwilling or unable to comply with all clinical investigation-required\n             follow-up evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients that are candidates for implantation of a St Jude Medical Portico replacement\n        aortic heart valve, or have been implanted with with a St. Jude Medical Portico valve as\n        part of a previous investigational device trial"
            }
        }, 
        "enrollment": {
            "#text": "1050", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802788", 
            "org_study_id": "CV-12-054-EU-PV"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B"
                ], 
                "intervention_name": "St Jude Medical Portico replacement aortic valve", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B"
                ], 
                "intervention_name": "Transcatheter Aortic Valve Implant", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "TAVI", 
                    "Transcatheter Aortic Valve Replacement", 
                    "TAVR"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Aortic Stenosis", 
            "Heart Valve Prosthesis", 
            "Trans Catheter Aortic Valve Replacement", 
            "TAVR", 
            "Trans Catheter Aortic Valve Implant", 
            "TAVI"
        ], 
        "lastchanged_date": "February 28, 2013", 
        "number_of_groups": "2", 
        "official_title": "International International Long-term Follow-up Study of Patients Implanted With a Portico\u2122 Valve", 
        "overall_contact": {
            "email": "SLeBail@sjm.com", 
            "last_name": "Sophie Le Bail", 
            "phone": "+322 774 6971"
        }, 
        "overall_contact_backup": {
            "email": "IDeBock@sjm.com", 
            "last_name": "Isabelle De Bock", 
            "phone": "+322 774 6822"
        }, 
        "overall_official": [
            {
                "affiliation": "Rigshopitalet University Hospital, Copenhagen", 
                "last_name": "Lars S\u00f8ndergaard, DMSc", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ospedale S. Raffaele, Milan", 
                "last_name": "Francesco Maisano, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "All-cause Mortality", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "All Cause Mortality", 
                "safety_issue": "No", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "description": "Any one of the following criteria:\nDeath due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure).\nDeath caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.\nAll procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure.\nAll valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse event.\nSudden or witnessed death.\nDeath of unknown cause.", 
                "measure": "Frequency of Cardiovascular Mortality as defined by the Valve Academic Research Consortium (VARC)", 
                "safety_issue": "No", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "description": "Please refer to the following publication for a detailed description of this and all further VARC defined endpoints:\nKappetein AP, Head SJ, G\u00e9n\u00e9reux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. The Journal of Thoracic and Cardiovascular Surgery 2013;145(1):6-23.", 
                "measure": "Frequency of Myocardial Infarction as defined by VARC", 
                "safety_issue": "No", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "measure": "Frequency of Stroke as defined by VARC.", 
                "safety_issue": "No", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "measure": "Frequency of Bleeding events as defined by VARC.", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "measure": "Frequency of Acute Kidney injury as defined by VARC", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "measure": "Frequency of Vascular and access related complications as defined by VARC", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "description": "In particular this includes the rate of pacemaker implantation at 30 days post procedure", 
                "measure": "Frequency of Conduction disturbances and cardiac arrythmias as defined by VARC.", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "description": "Conversion to open surgery\nUnplanned use of cardiopulmonary bypass (CPB)\nCoronary obstruction\nVentricular septal perforation\nMitral valve apparatus damage or dysfunction\nCardiac tamponade\nEndocarditis\nValve thrombosis\nValve malpositioning\nTranscatheter valve in Transcatheter valve deployment", 
                "measure": "Frequency of other TAVI related complications as defined by VARC.", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "description": "Prosthetic valve stenosis\nProsthetic valve regurgitation", 
                "measure": "Prosthetic valve function as defined by VARC", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant."
            }, 
            {
                "description": "Absence of procedural mortality AND\nCorrect positioning of a single prosthetic heart valve into the proper anatomical location AND\nIntended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, AND no moderate or severe prosthetic valve regurgitation)", 
                "measure": "VARC defined \"device success\" composite endpoint", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "All-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury\u2014Stage 2 or 3 (including renal replacement therapy)\nCoronary artery obstruction requiring intervention\nMajor vascular complication\nValve-related dysfunction requiring repeat procedure (Balloon Aortic Valvuloplasty (BAV), Trans Catheter Aortic Valve Implant (TAVI), or Surgical Aortic Valve Replacement (SAVR))", 
                "measure": "VARC defined \"Early Safety\" composite endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "All-cause mortality\nAll stroke (disabling and non-disabling)\nRequiring hospitalizations for valve-related symptoms or worsening congestive heart failureb\nNYHA (New york Heart Association) class III or IV functional classification of heart failure.\nValve-related dysfunction (mean aortic valve gradient \u226520 mmHg, Effective Orifice Area (EOA) \u22640.9-1.1 cm2(c) and/or Doppler Velocity Integral (DVI) <0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitationa", 
                "measure": "VARC defined \"Clinical Efficacy\" composite endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "From 30 days post procedure to  completion of follow up at 5 years."
            }, 
            {
                "description": "Structural valve deterioration\nValve-related dysfunction (mean aortic valve gradient\n\u226520 mmHg, EOA \u22640.9-1.1 cm2cand/or DVI <0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitationa)\nRequiring repeat procedure (TAVI or SAVR)\nProsthetic valve endocarditis\nProsthetic valve thrombosis\nThrombo-embolic events (e.g. stroke)\nVARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)", 
                "measure": "VARC defined \"Time-related valve safety\" composite endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "From device implant  to  completion of follow up at 5 years."
            }, 
            {
                "measure": "New York Heart Association (NYHA) Functional classification of heart failure.", 
                "safety_issue": "No", 
                "time_frame": "Change in NYHA class between baseline and 30 days, 6 months, 1, 2, 3, 4 and 5 years"
            }, 
            {
                "description": "Distance in metres that the participant can walk in 6 minutes.", 
                "measure": "Six minute walk test (6MWT)", 
                "safety_issue": "No", 
                "time_frame": "Change between baseline and 30 days, 6 months, 1, 2, 3, 4 and 5 years"
            }, 
            {
                "description": "Quality of life is quantified using the EQ-5D-5L questionnaire.", 
                "measure": "Quality of Life Assessment.", 
                "safety_issue": "No", 
                "time_frame": "Change in Quality of Life from Baseline to 30 days, 6 months, 1, 2, 3, 4 and 5 years"
            }
        ], 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}